G. Hortobagyi

Publications1,757
h-index166
Citations107,156
Highly Influential Citations3,594
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Buzdar
  • 780 Publications • 54,059 Citations
  • M. Hung
  • 926 Publications • 71,806 Citations
  • V. Valero
  • 736 Publications • 33,841 Citations
  • J. Baselga
  • 1,177 Publications • 125,082 Citations
  • Publications
  • Influence
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
TLDR
It is reported that PTEN activation contributes to trastuzumab's antitumor activity and PTEN deficiency is a powerful predictor for trastzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance. Expand
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
TLDR
Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival, however, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with other patients, particularly in the first 3 years. Expand
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
TLDR
Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors. Expand
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
TLDR
The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers. Expand
Breast carcinoma in men
TLDR
The goals of the current study were to fill in the major gaps in knowledge regarding the incidence, presenting characteristics, prognostic factors, and survival rates of male breast carcinoma and to determine how Breast carcinoma differs between men and women. Expand
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
TLDR
Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses. Expand
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene…
TLDR
It is shown that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology and induce cancer cell EMT via STAT3-mediated TWIST gene expression. Expand
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
TLDR
A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy. Expand
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
TLDR
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value. Expand
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
TLDR
This study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS–ERK and MDM2 and downregulates Forkhead box O 3a by directly interacting with and phosphorylating FOXO 3a at Ser 294, Ser 344 and Ser 425. Expand
...
1
2
3
4
5
...